Emerging Immunotargets and Immunotherapies in Prostate Cancer
- PMID: 26898309
- DOI: 10.2174/1389450117666160217123304
Emerging Immunotargets and Immunotherapies in Prostate Cancer
Abstract
Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo- or radiation therapy.
Similar articles
-
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.
-
Checkpoint inhibitors: outstanding efficacy but at what cost?Curr Opin Oncol. 2016 Jul;28(4):253. doi: 10.1097/CCO.0000000000000305. Curr Opin Oncol. 2016. PMID: 27163724 No abstract available.
-
Immune Checkpoint Therapies in Prostate Cancer.Cancer J. 2016 Mar-Apr;22(2):117-20. doi: 10.1097/PPO.0000000000000176. Cancer J. 2016. PMID: 27111907 Free PMC article. Review.
-
Emerging Immunotargets in Metastatic Renal Cell Carcinoma.Curr Drug Targets. 2016;17(7):771-6. doi: 10.2174/1389450117666151209115753. Curr Drug Targets. 2016. PMID: 26648075 Review.
-
B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.Tumori. 2015 Sep-Oct;101(5):549-54. doi: 10.5301/tj.5000326. Epub 2015 May 30. Tumori. 2015. PMID: 26045125 Review.
Cited by
-
Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers.Cancers (Basel). 2019 Aug 22;11(9):1225. doi: 10.3390/cancers11091225. Cancers (Basel). 2019. PMID: 31443386 Free PMC article. Review.
-
rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy.Int J Mol Sci. 2019 Apr 27;20(9):2082. doi: 10.3390/ijms20092082. Int J Mol Sci. 2019. PMID: 31035590 Free PMC article.
-
Potentiating prostate cancer immunotherapy with oncolytic viruses.Nat Rev Urol. 2018 Apr;15(4):235-250. doi: 10.1038/nrurol.2018.10. Epub 2018 Feb 13. Nat Rev Urol. 2018. PMID: 29434366 Review.
-
Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy.Onco Targets Ther. 2017 Jul 14;10:3485-3491. doi: 10.2147/OTT.S135873. eCollection 2017. Onco Targets Ther. 2017. PMID: 28761357 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials